By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cirius Therapeutics 

12651 High Bluff Drive
Suite 150
San Diego  California  92130  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

Cirius Therapeutics, a clinical-stage pharmaceutical company, is developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin sensitizing mechanism of action, MSDC-0602K has potential to resolve the underlying pathophysiology of NASH.

YEAR FOUNDED:

2016

LEADERSHIP:

Founder: Jerry Colca

CEO: Bob Baltera

CMO: Howard Dittrich

CBO: Brian Farmer

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Private

Web Site: Cirius Therapeutics
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Currently No News Articles
//-->